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Aim: To investigate the influence of exogenous lactoferrin (LF) on tumor growth, energy and lipid metabolism of Walker-256 carci-
nosarcoma and to assess genotoxic effects of LF. Materials and Methods: The study was performed on Walker-256 tumor-bearing 
rats. Total lipids and phospholipids were determined by thin-layer chromatography. Comet assay was used to investigate the geno-
toxic effects of LF. Results: Daily i.p. administrations of exogenous LF at concentrations of 1 mg/kg and 10 mg/kg starting from 
the 4th day after tumor transplantation suppressed growth of Walker-256 carcinosarcoma by almost 44%. After treatment with 
recombinant LF in both doses, the phospholipid composition of Walker-256 carcinosarcoma cells was changed (3-fold increase 
of phosphatidylethanolamine, 3.4-fold increase of phosphatidylcholine, and 1.8-fold increase of sphingomyelin, while the cardiolipin 
content decreased by 67%. Exogenous LF was not genotoxic for bone marrow cells (as assessed by the ratio of PCE/NCE, number 
of micronuclei) and peripheral blood lymphocytes (percentage of DNA in the tail of a comet) in Walker-256 carcinosarcoma-bearing 
rats. Conclusion: Exogenous LF caused the inhibition of Walker-256 carcinosarcoma growth and a decrease in the microviscosity 
of plasma cell membranes, and exerted no genotoxicity toward bone marrow cells and peripheral blood of experimental animals.
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Breast cancer (BC) is one of the most common 
forms of cancer in women worldwide [1]. Despite the 
rapid development of modern oncology, the incidence 
of BC in Ukraine and in most developed countries con-
tinues to grow, which makes this problem extremely 
relevant [1–3]. One of the causes of high mortality 
from BC is the high heterogeneity of this disease, 
both in morphological and molecular characteristics, 
and in clinical course [4–6], which requires different 
approaches to diagnosis and treatment. Data from 
clinical and experimental studies confirm the impor-
tance of iron metabolism disorders in the onset and 
progression of cancer [7, 8]. Today, considerable 
attention is paid to metal-containing proteins, which 
are important components of iron metabolism and 
play a role in malignant transformation and tumor 
progression. There is evidence that the concentration 
of iron and proteins involved in iron metabolism cor-
relates with the aggressiveness of a number of tumors, 
including BC [9, 10].
Human lactoferrin (LF) is an 80-kDa glycoprotein 
from the family of iron-binding proteins. It is a single 
chain polypeptide composed of 692 amino acids. This 
protein is produced by epithelial cells and is found 
in mucosal secretions such as tears, saliva, nasal 
exudates, gastrointestinal fluids, seminal, and vaginal 
fluids [11]. Synthesis and secretion of LF can occur 
constitutionally (e.g., in secretory glands) or under the 
control of sex hormones. It has been described that 
LF can suppress the growth of solid tumors and strong-
ly inhibit experimental metastasizing in mice [12]. 
An important feature of LF is its ability to bind to nucleic 
acids and to regulate cell cycle, proliferative activity 
of cells, and to affect the pro- and antioxidant balance 
in the cells. Human LF is a multifunctional glycoprotein 
that can inhibit cancer cells at G2/M phase [11, 13].
The present study is focused on the effects of re-
combinant human LF on tumor growth, energy and 
lipid metabolism of Walker-256 carcinosarcoma cells 
in vivo.
MATERIALS AND METHODS
Design of the in vivo experiment. The study 
was conducted on female rats (N = 30) with trans-
planted Walker-256 carcinosarcoma. This tumor 
strain was obtained from National Bank of Cell Lines 
and Transplanted Tumors of R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy (IEPOR), National Academy of Sciences (NAS) 
of Ukraine (Kyiv, Ukraine). The keeping of animals, 
all stages of experimental researches, including eu-
thanasia, met the conventional international require-
ments of humane treatment of laboratory animals, 
and regulations approved by bioethics commission 
of the R.E. Kavetsky IEPOR, NAS of Ukraine.
Three groups (10 animals each) were formed: 
1 — control, 2 — animals treated with exogenous 
LF at a dose of 1 mg/kg, 3 — animals treated with 
exogenous LF at a dose of 10 mg/kg of body weight. 
Daily i.p. administration of exogenous LF started from 
the 4th day after tumor transplantation.
Twelve days after the tumor transplantation, the 
antitumor activity of LF, the phospholipid composition 
of tumor cell membranes and the genotoxic effects 
of LF were analyzed.
Tumor volume was calculated by the formula:
V = a · b · c · π/6,
where а, b, c — orthogonal parameters of tumor.
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Percentage of tumor growth inhibition was deter-
mined by the formula:
Inhibition% = (Control — Experiment)/ 
Control · 100%,
where Control and Experiment are indicators of tu-
mor volume in the control and experimental groups 
of animals.
Mitochondria study. Oxidative phosphorylation 
indices of tumor cell mitochondria were determined 
according to [14].
Thin-layer chromatography. The isolation 
of plasma membranes from the tumor cells of rats was 
carried out by the method of differential ultracentrifu-
gation in sucrose density gradient [15]. Concentration 
of protein in suspension of plasma membranes was 
determined by Lowry method. The purity of membrane 
specimens was controlled by the activity of marker 
enzymes Na+, K+-ATPase and 5’- nucleotidase.
Total lipid content in membranes of Walker-256 car-
cinosarcoma cells (phospholipids, cholesterol, di- and 
triglycerides and ethers of cholesterol) has been 
determined. In addition, the following individual phos-
pholipids were evaluated: lysophosphatidylcholine, 
sphingomyelin, phosphatidylserine, phosphatidylino-
sitol, phosphatidylcholine, phosphatidylethanolamine, 
cardiolipin.
The qualitative and quantitative composition of total 
lipids and phospholipids was determined by thin-
layer chromatography method using plates “Sorbfil” 
PTSH-AF-A (“Imid Ltd”, Krasnodar, Russia) accord-
ing to standard procedures [16]. The lipids from the 
Walker-256 tissue were extracted using a chloroform/
methanol mixture (1:1, v/v). The thin-layer chroma-
tography of total lipids was carried out only in one 
direction in the hexane/diethyl ether/glacial acetic 
acid solvent system (85:15:1, v/v) [16]. The thin-layer 
chromatography of phospholipids was carried out 
in two mutually perpendicular directions [17]. The first 
solvent system was chloroform/methanol/benzene/
ammonia (65:30:10:6, v/v). The second system was 
chloroform/methanol/benzene/acetone/glacial acetic 
acid/water (70:30:10:5:4:1, v/v). After the evapora-
tion of the solvents the plates were treated with 10% 
H2SO4 in methanol and heated for 5 min at 180 °C. All 
chromatograms were scanned and scans were im-
aged with the program Picture J. Lipid content was 
expressed in µgP/g of the tissue.
Comet assay. A standard classical method 
of alkaline gel electrophoresis of isolated cells was 
performed as described in [13]. Microscopic analysis 
was performed using a fluorescent microscope Axio 
Scope A.1 (Carl Zeiss, Germany). For each analyzed 
specimen at least 100 “DNA-comets” were used. Digi-
tal images were analyzed by the computer program 
“CometScore” (TriTek Corp., USA).
Calculations of micronuclei (MN) were performed 
on a Axio Scope A.1 (Carl Zeiss, Germany) fluorescence 
microscope with magnification x400 by determining the 
number of cells with MN per 1000 polychromatophilic 
erythrocytes (PCE). In addition, the ratio of PCE to nor-
mochromatophilic erythrocytes (NCE) as an indicator 
of the cytotoxic effect (per 2000 cells) was evaluated. 
Following acridine orange staining, PCE had an orange 
color, NCE — green, and MN — bright yellow. It should 
be noted that the MN, which were detected in the NCE, 
were stained in light green.
Statistical analysis. Experimental data were 
analyzed using the Student’s t-test. p-values less than 
0.05 were considered statistically significant. Statisti-
cal analysis of the obtained data was performed using 
the STATISTICA 6.0 software.
RESULTS AND DISCUSSION
Numerous in vitro and in vivo studies have shown 
that LF is capable of inhibiting carcinogenesis in the 
mammary gland, esophagus, lungs and liver [18–21]. 
Thus, it has been shown that bovine LF is able to re-
duce proliferative activity and migration of HS578T and 
T47D cells [18]. The administration of LF in the animal 
diet led to the inhibition of the development of papil-
lomavirus in rats, as well as adenomas and carcinomas 
in the lungs of rats, which were treated sequentially 
with diethylnitrosamine (DEN, i.p.), dihydroxy-di-N-
propylnitrosamine (DHPN, in drinking water) and N-
nitrosomethylbenzylamine (NMBA, s.c.) during the 
first 8 weeks [19] and showed chemopreventive action 
against tongue carcinogenesis initiated with 4-nitro-
quinoline 1-oxide (4-NQO) in male F344 rats [20].
According to our results, LF administered at a dose 
of 10 mg/kg of body weight inhibited the growth 
of Walker-256 carcinosarcoma by 44.5% (p < 0.05) 
compared with that in the control group (Fig. 1). A simi-
lar result was obtained with the use of LF at a dose 
of 1 mg/kg, which led to tumor growth retardation 
by 43.6% (p < 0.05).
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Fig. 1. Effect of exogenous LF on the growth of Walker-256 car-
cinosarcoma. *p < 0.05 compared to the control
One of the causes for tumor growth retarda-
tion after 9 injections of exogenous LF at the doses 
of 1 mg/kg and 10 mg/kg of body weight may be the 
suppression of oxidative phosphorylation of the mito-
chondria in the Walker-256 carcinosarcoma cells. The 
results of the study are presented in Fig. 2.
As it is evident from the data, exogenous LF ad-
ministered at doses of 1 mg/kg and 10 mg/kg of body 
weight led to a decrease in the rate of oxygen uptake 
by mitochondria in the phosphorylating state, that 
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is, during the synthesis of ATP (V3 index), by 13% 
and 20%, respectively (p ≤ 0.05). Moreover, such 
changes were observed only during oxidation 
of glutamate (NAD-dependent substrate), but 
not recorded during oxidation of succinate (FAD-
dependent substrate). This indicates that LF is likely 
to affect only the first Fe-S complex of the mitochon-
drial respiratory chain.
It is known that for the normal passage of the 
cell cycle the anabolism of the lipids of the mem-
branes should be increased, which is accompanied 
by a change in their architecture. The production 
of phospholipids, which are essential for cell growth, 
occurs at different stages of the cell cycle.
Growth and proliferation of cells require certain in-
tegrity of the plasma membranes and membranes of or-
ganelles. The composition of specific lipids, which form 
membranes of cells and organelles in proliferating cells, 
is important for cellular homeostasis. For example, the 
relative content of key components of membranes, such 
as phosphatidyl ethanolamine and phosphatidylcholine, 
are necessary for the optimal functioning of the endo-
plasmic reticulum [22, 23].
Therefore, we investigated the effect of LF on the 
phospholipid composition of Walker-256 carcinosar-
coma cells. The results are shown in Fig. 3. As can 
be seen from the data shown in Fig. 3, a, nine injections 
of LF at a dose of 1 mg/kg led to a significant increase 
in phosphatidylethanolamine, phosphatidylcholine 
and sphingomyelin — by 86; 89 and 50%, respec-
Fig. 2. Effect of LF on the rate of oxygen consumption by the 
mitochondria of the Walker-256 carcinosarcoma cells in the 
phosphorylating state (indicator V3), the oxidation substrate 
is glutamate; n = 10; *p < 0.05 compared to the control
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Fig. 3. Effect of LF on the phospholipid composition of Walker-256 carcinosarcoma cells (n = 9): a — 9 injections of LF in a dose 
of 1 mg/kg; b — 9 injections of LF in a dose of 10 mg/kg. *p < 0.05 compared to control
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tively. Against this background, there was observed 
a tendency to the decrease of the cardiolipin content 
(by 33%).
At a dose of 10 mg/kg, the content of phospholipids 
underwent even more evident change (Fig. 3, b). The 
level of phosphatidyl ethanolamine increased by 3 times, 
phosphatidylcholine — increased by 3.4 times, sphin-
gomyelin — by 1.8 times. Again, it is worth paying atten-
tion to the reduction of the cardiolipin content (by 67%) 
(Fig. 3, b). It is supposed that this phospholipid can inte-
grate elements of the respiratory chain of mitochondria 
into an integral structure, which, in turn, includes the 1st 
Fe-S complex [23]. In addition, it is believed that before 
the beginning of apoptosis the interaction of cardiolipin 
with cytochrome c is disturbed, which may change the 
integrity of the mitochondrial membrane [23].
However, in our opinion, the most important thing 
is that LF has led to an increase in the phosphatidyl-
choline/sphingomyelin ratio (Fig. 4).
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Fig. 4. Effect of LF on the phosphatidylcholine/sphingomyelin 
ratio in Walker-256 carcinocarcinoma cells (n = 9): a — 9 injec-
tions of LF in a dose of 1 mg/kg; b — 9 injections of LF in a dose 
of 10 mg/kg. *p <0.05 compared to control
At a dose of 1 mg/kg, this ratio increased by 27%, 
and when LF was administered at a dose of 10 mg/kg, 
this index increased by 87% (p < 0.05). This indicates 
a decrease in the microviscosity and an increase in the 
fluidity of the plasma membranes of cells, which leads 
to changes in the compartmentalization of biologically 
active molecules in the cell. As a consequence, the cell 
cannot continue to function normally and to proliferate.
The literature data indicate that the classical me-
thod for determining the genotoxic effects of various 
factors on living organisms is the Hayashi method, 
which is based on the study of changes in the PCE 
to NCE ratio in bone marrow (BM). The shift of the 
PCE/NCE ratio in the BM is an indicator of cytotoxic 
action, and an increase in the MN number — of geno-
toxic one [24, 25]. In a number of reports, an attention 
has been paid to a certain complexity in the evalua-
tion of MN in the cells of the erythroid lineage, which 
is associated with the specificity of maturation of these 
cells, namely, the “removal” of the nucleus from the 
erythroblast, the delay of certain nucleus fragments, 
followed by their elimination [26]. That is why the 
quantitative definition of MN is proposed to be carried 
out in PCE. We have used the MN test in BM cells only, 
since, according to some authors, counting MN and 
the PCE/NCE ratio in peripheral blood has several 
disadvantages: low PCE content and the possibility 
of MN elimination in NCE [27, 28].
Despite the information on the wide range 
of LF effects on various parts of the pathophysi-
ological process in carcinogenesis, in literature there 
is virtually no study of possible mechanisms of toxic 
effects of LF in vivo. It is believed that an increasing 
load of “free” iron can take part in the mechanism 
of cytotoxi city and genotoxicity during carcinogen-
esis, which in turn may be changed under the action 
of exogenous iron-binding protein LF. Using the 
model of Walker- 256 carcinosarcoma, we showed 
that LF at a concentration of 1 mg/kg did not exert 
the genotoxic and cytotoxic effects on the BM cells 
of erythroid lineage (p > 0.01) compared with the 
control group (Table 1).
Table 1. MN (‰) and the PCE/NCE ratio in BM of animals with  
Walker-256 carcinosarcoma under the influence of different concentra-
tions of exogenous LF
LF dose PCE/NCE MN, %
Control 0.99 ± 0.03 0.50 ± 0.25
1 mg/kg 0.93 ± 0.02 1.01 ± 0.25
10 mg/kg 0.82 ± 0.03 1.25 ± 0.20
Along with this, LF at a concentration of 10 mg/kg also 
did not lead to significant changes in the amount 
of MN and the PCE/NCE ratio (Table 1). There 
is a slight tendency to the shift of the PCE/NCE ratio 
towards immature erythrocytes in animals with Walker-
 256 carcinosarcoma after the introduction of exoge-
nous LF at a dose of 10 mg/kg, which suggests that 
LF may insignificantly inhibit erythropoiesis. However, 
as can be seen from the data, the average values of the 
PCE/NCE ratio in the animals treated with the maximum 
concentration of LF remained within the control values. 
Thus, the study of the possible genotoxic and cytotoxic 
effects of exogenous LF in the group of animals with 
Walker-256 carcinosarcoma did not reveal any signifi-
cant changes in the morphology of the BM cells of the 
erythroid lineage.
In some experimental studies in vitro, it has been 
shown that one of the possible mechanisms of geno-
toxic action of LF can be double-strand DNA breaks 
due to the increased phosphorylation of histone 
a
b
204 Experimental Oncology 40, 200–204, 2018 (September)
H2A.X. However, we have shown that the used con-
centrations of LF did not cause the genome instability 
in the MB cells of the erythroid lineage in animals with 
Walker-256 carcinosarcoma (Table 2).
Table 2. Effect of exogenous LF on peripheral blood lymphocytes in rats 
with Walker-256 carcinosarcoma
LF dose  DNA in the tail of the comets, %
Positive control (+Н2О2) 47.3 ± 4.2
Control 5.3 ± 0.7
1 mg/kg 6.9 ± 0.5
10 mg/kg 6.8 ± 0.4
As can be seen from the data presented, the per-
centage of DNA in the tail of the comets did not exceed 
significantly the control values at both concentrations 
of exogenous LF.
In conclusion, the obtained data showed that 
LF in vivo did not exert genotoxic and cytotoxic ef-
fects, as evidenced by the results of a study of BM and 
the percentage of DNA in the tail of the comet. This 
indicates the need for further study of the molecular 
biological effects and mechanisms of the influence 
of exogenous LF and points to the prospect of its use 
in clinical practice.
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